Developer docs
API playgroundTry for free, no card

Search company profiles

Olatec Therapeutics

Full company profile

uuid00006ah

Namestring
Olatec Therapeutics
Legal namestring
Olatec Therapeutics LLC
Websiteurl
olatec.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Olatec Therapeutics is a privately held, clinical-stage biopharmaceutical company developing a platform of oral NLRP3 antagonist therapeutics to treat and prevent acute and chronic inflammatory diseases mediated by Interleukin-1. The company's lead compound, dapansutrile (OLT1177®), is a selective small-molecule inhibitor that binds NLRP3 to prevent formation of the NLRP3 inflammasome, thereby inhibiting production of the pro-inflammatory cytokines IL-1β and IL-18. Dapansutrile is described as the only known selective NLRP3 inhibitor in Phase 2 clinical trials in the US and Europe, and Olatec's broader platform includes approximately 40–60 structurally related OLT Analogues protected by a portfolio of over 180 patents and patent applications globally.

The company is advancing dapansutrile in parallel Phase 2 programs across multiple indications: gout (PODAGRA-II), Parkinson's disease (DAPA-PD at Cambridge University Hospitals), type 2 diabetes (DAPAN-DIA at University Hospital Basel), and PD-1 refractory advanced melanoma in combination with pembrolizumab (DREAM at Duke Cancer Institute, in collaboration with Merck). Earlier-stage work includes a Phase 1b heart failure trial that met safety and biomarker endpoints, preclinical Parkinson's data, and a topical gel formulation that has completed Phase 2 in knee osteoarthritis. The company is led by Founder/CEO Damaris B. Skouras, with scientific leadership from co-CSOs Charles A. Dinarello (recipient of the 2020 Tang Prize in Biopharmaceutical Science) and Joseph St. Laurent.

Olatec is headquartered in New York with a wholly-owned subsidiary, Olatec Therapeutics BV, in the Netherlands, and conducts operations across the US and Europe. The company has raised over $75 million in private capital since inception, anchored by a $40 million Series A in February 2023 led by Sanders Morris Harris, supplemented by non-dilutive funding from The Michael J. Fox Foundation, Cure Parkinson's, Van Andel Institute, the EU Horizon Europe Programme, and the Swiss Government. As a pre-revenue clinical-stage company, Olatec does not currently sell approved products; commercial revenue is expected upon potential future regulatory approval and commercialization of dapansutrile or other platform assets.

Short descriptiontext

Olatec Therapeutics is a privately held, clinical-stage biopharmaceutical company developing oral selective NLRP3 inflammasome inhibitors led by dapansutrile (OLT1177®) to treat acute and chronic inflammatory diseases, with Phase 2 trials ongoing in gout, Parkinson's disease, type 2 diabetes, and melanoma.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
NLRP3 inhibitors, inflammatory disease therapeutics, clinical-stage biopharmaceutical, small molecule therapeutics, IL-1 beta inhibition
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Inflammatory Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Commercialization
TypeOne Time License
Description

Olatec is a pre-revenue clinical-stage biopharmaceutical company. The company is developing dapansutrile across multiple inflammatory disease indications including gout, Parkinson's disease, type 2 diabetes, heart failure, and melanoma. Revenue will be generated through future product sales upon regulatory approval and commercialization.

olatec.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1OLT1177®
Description

Pharmaceutical grade formulation of dapansutrile, a registered trademark of Olatec Therapeutics in the United States and other countries.

olatec.com
Core offering1 text field

Olatec Therapeutics is a privately held, clinical-stage biopharmaceutical company developing dapansutrile (OLT1177®), an oral selective NLRP3 inflammasome inhibitor that blocks the production of pro-inflammatory cytokines IL-1β and IL-18, for the treatment of acute and chronic inflammatory diseases including gout, heart failure, type 2 diabetes, Parkinson's disease, melanoma, and other IL-1 mediated conditions. The company also maintains a broader platform of approximately 40-60 structurally related OLT Analogues.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Phase 2a gout trial met primary and secondary endpoints demonstrating clinical benefit, safety, and reduction in systemic inflammation
+3 more records
Product overview1 text field

Olatec Therapeutics is a privately held biopharmaceutical company developing a platform of oral NLRP3 antagonist therapeutics. The company's core product is dapansutrile (lab code: OLT1177®), the only known selective NLRP3 inflammasome inhibitor in Phase 2 clinical trials. In addition to dapansutrile, the platform includes approximately 40-60 structurally related OLT Analogues. The company is developing dapansutrile across multiple inflammatory disease indications including acute gout flares (PODAGRA trials), heart failure, type 2 diabetes (DAPAN-DIA), Parkinson's disease (DAPA-PD), and oncology (DREAM trial with pembrolizumab in melanoma). The company also developed a topical gel formulation of dapansutrile for osteoarthritis which completed Phase 2 trials.

Product and service3 records
1Dapansutrile (OLT1177®)
CategoryLead pharmaceutical compound (NLRP3 inhibitor)
Description

Dapansutrile (lab code: OLT1177®) is Olatec's lead compound — an oral, selective small-molecule NLRP3 inflammasome inhibitor that prevents formation of the NLRP3 inflammasome and inhibits production of pro-inflammatory cytokines IL-1β and IL-18. It is being developed for patients with acute and chronic inflammatory diseases mediated by Interleukin-1, including acute gout flares (PODAGRA trials), heart failure, type 2 diabetes (DAPAN-DIA), Parkinson's disease (DAPA-PD), and advanced melanoma (DREAM trial in combination with pembrolizumab).

2OLT Analogues Platform
CategoryPharmaceutical compound platform
Description

Platform of approximately 40-60 structurally related NLRP3 inhibitor compounds (OLT Analogues), representing a new class of pharmaceuticals for treating inflammatory diseases beyond the lead compound dapansutrile. Protected by a global patent portfolio of more than 180 patents and patent applications.

3OLT1177® Gel (Topical Dapansutrile)
CategoryTopical pharmaceutical formulation
Description

Topical gel formulation of dapansutrile (OLT1177®) that has completed Phase 2 clinical trials for treatment of moderate-to-severe osteoarthritis of the knee.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The DAPA-PD Phase 2 clinical trial is being conducted at Cambridge University Hospitals under principal investigator Dr. Caroline Williams-Gray. The trial evaluates dapansutrile safety, tolerability, inflammation biomarkers, and preliminary efficacy over 12 months in early-stage Parkinson's disease patients.

2Medical University of Innsbruck
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Dr. Nadia Stefanova at the Medical University of Innsbruck for preclinical Parkinson's disease studies funded by The Michael J. Fox Foundation, assessing dapansutrile's effects on motor symptoms and neuroinflammation in transgenic mouse models.

olatec.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The DREAM Trial (Phase 1/2) evaluating dapansutrile in combination with pembrolizumab (Keytruda) in patients with PD-1 refractory advanced melanoma is being led by Principal Investigator April Salama MD at The Duke Cancer Institute.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Merck supports the DREAM Trial investigating dapansutrile (OLT1177) in combination with pembrolizumab (Keytruda) for PD-1 refractory advanced melanoma. The collaboration addresses inflammatory-driven resistance to anti-PD-1 therapies.

5University Hospital Basel / University of Basel
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Marc Donath, Chief Physician in Endocrinology, Diabetes and Metabolism at University of Basel, serves as Principal Investigator for the DAPAN-DIA Phase 2 trial in type 2 diabetes. Dr. Donath was recently appointed Medical Director of the Diabetes Centre at University Hospital Montreal.

olatec.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership with National Jewish Health for the Phase 2 clinical trial of dapansutrile in COVID-19, led by Principal Investigator Dr. Michael Wechsler.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage immunology biotech developing IL-1 pathway antibodies (e.g., anti-IL-1R). Comparable as an inflammation-focused biotech targeting the same IL-1 axis Olatec's NLRP3 platform modulates.

TypeDirect peer
Description

IFM developed small-molecule NLRP3 inhibitors (IFM-2427/NDPK-A) and was acquired by BMS in 2017 for up to $2.3B. It is the most direct competitor in the selective oral NLRP3 space, with deeper resources behind the same target Olatec is pursuing.

3Inflazome (now Roche)
TypeDirect peer
Description

Inflazome developed brain-penetrant NLRP3 inhibitors and was acquired by Roche in 2020 for €380M. It is the closest direct peer in NLRP3 inhibition with a similar small-molecule, orally bioavailable approach across inflammatory diseases.

TypeDirect peer
Description

Private UK-based biotech developing brain-penetrant NLRP3 inhibitors for inflammatory and neurodegenerative diseases. Directly comparable to Olatec as a clinical-stage, venture-backed NLRP3 platform play.

TypeBroad incumbent
Description

Acquired IFM Tre's NLRP3 program from BMS in 2019 and is advancing multiple NLRP3 candidates. Comparable as a broad incumbent developing selective NLRP3 inhibitors across inflammatory indications.

TypeEmerging player
Description

Emerging biotech focused on NLRP3 inflammasome inhibition for inflammatory diseases. Comparable as an early-stage player targeting the same pathway with selective small-molecule approaches.

7Bristol-Myers Squibb
TypeBroad incumbent
Description

Holds the IFM Tre-derived NLRP3 program following its 2017 acquisition of IFM Therapeutics. As a large incumbent with multiple NLRP3 candidates in development, BMS represents a key competitive and potential M&A counterparty.

TypeRegional player
Description

Indian pharmaceutical company developing its own NLRP3 inhibitor program. Comparable as a regional player pursuing the same target class, though primarily serving the Indian market.

9ChemoCentryx (Amgen)
TypeEmerging player
Description

Developed avacopan (Tavneos), an anti-C5aR therapy addressing IL-1-driven inflammation, and was acquired by Amgen in 2022. Comparable as an IL-1 pathway-adjacent biotech commercializing inflammation therapeutics.

TypeEmerging player
Description

Commercial-stage immunology biotech with multiple inflammation assets. Comparable as a clinical-to-commercial-stage company developing therapeutics for IL-1-mediated and other inflammatory diseases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Olatec Therapeutics

Inflammatory Disease Therapeuticsolatec.com

Olatec Therapeutics is a privately held, clinical-stage biopharmaceutical company developing oral selective NLRP3 inflammasome inhibitors led by dapansutrile (OLT1177®) to treat acute and chronic inflammatory diseases, with Phase 2 trials ongoing in gout, Parkinson's disease, type 2 diabetes, and melanoma.

What Olatec Therapeutics does

Olatec Therapeutics is a privately held, clinical-stage biopharmaceutical company developing a platform of oral NLRP3 antagonist therapeutics to treat and prevent acute and chronic inflammatory diseases mediated by Interleukin-1. The company's lead compound, dapansutrile (OLT1177®), is a selective small-molecule inhibitor that binds NLRP3 to prevent formation of the NLRP3 inflammasome, thereby inhibiting production of the pro-inflammatory cytokines IL-1β and IL-18. Dapansutrile is described as the only known selective NLRP3 inhibitor in Phase 2 clinical trials in the US and Europe, and Olatec's broader platform includes approximately 40–60 structurally related OLT Analogues protected by a portfolio of over 180 patents and patent applications globally.

The company is advancing dapansutrile in parallel Phase 2 programs across multiple indications: gout (PODAGRA-II), Parkinson's disease (DAPA-PD at Cambridge University Hospitals), type 2 diabetes (DAPAN-DIA at University Hospital Basel), and PD-1 refractory advanced melanoma in combination with pembrolizumab (DREAM at Duke Cancer Institute, in collaboration with Merck). Earlier-stage work includes a Phase 1b heart failure trial that met safety and biomarker endpoints, preclinical Parkinson's data, and a topical gel formulation that has completed Phase 2 in knee osteoarthritis. The company is led by Founder/CEO Damaris B. Skouras, with scientific leadership from co-CSOs Charles A. Dinarello (recipient of the 2020 Tang Prize in Biopharmaceutical Science) and Joseph St. Laurent.

Olatec is headquartered in New York with a wholly-owned subsidiary, Olatec Therapeutics BV, in the Netherlands, and conducts operations across the US and Europe. The company has raised over $75 million in private capital since inception, anchored by a $40 million Series A in February 2023 led by Sanders Morris Harris, supplemented by non-dilutive funding from The Michael J. Fox Foundation, Cure Parkinson's, Van Andel Institute, the EU Horizon Europe Programme, and the Swiss Government. As a pre-revenue clinical-stage company, Olatec does not currently sell approved products; commercial revenue is expected upon potential future regulatory approval and commercialization of dapansutrile or other platform assets.

Olatec Therapeutics firmographics

Firmographics
Name
Olatec Therapeutics
Legal name
Olatec Therapeutics LLC
Website
https://olatec.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Olatec Therapeutics is a privately held, clinical-stage biopharmaceutical company developing oral selective NLRP3 inflammasome inhibitors led by dapansutrile (OLT1177®) to treat acute and chronic inflammatory diseases, with Phase 2 trials ongoing in gout, Parkinson's disease, type 2 diabetes, and melanoma.
Ownership category
akta.pro rank

Where Olatec Therapeutics is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Olatec Therapeutics business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Development and Commercialization: Olatec is a pre-revenue clinical-stage biopharmaceutical company. The company is developing dapansutrile across multiple inflammatory disease indications including gout, Parkinson's disease, type 2 diabetes, heart failure, and melanoma. Revenue will be generated through future product sales upon regulatory approval and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Olatec Therapeutics product offering

Product offering

Core offering

Olatec Therapeutics is a privately held, clinical-stage biopharmaceutical company developing dapansutrile (OLT1177®), an oral selective NLRP3 inflammasome inhibitor that blocks the production of pro-inflammatory cytokines IL-1β and IL-18, for the treatment of acute and chronic inflammatory diseases including gout, heart failure, type 2 diabetes, Parkinson's disease, melanoma, and other IL-1 mediated conditions. The company also maintains a broader platform of approximately 40-60 structurally related OLT Analogues.

Product overview

Olatec Therapeutics is a privately held biopharmaceutical company developing a platform of oral NLRP3 antagonist therapeutics. The company's core product is dapansutrile (lab code: OLT1177®), the only known selective NLRP3 inflammasome inhibitor in Phase 2 clinical trials. In addition to dapansutrile, the platform includes approximately 40-60 structurally related OLT Analogues. The company is developing dapansutrile across multiple inflammatory disease indications including acute gout flares (PODAGRA trials), heart failure, type 2 diabetes (DAPAN-DIA), Parkinson's disease (DAPA-PD), and oncology (DREAM trial with pembrolizumab in melanoma). The company also developed a topical gel formulation of dapansutrile for osteoarthritis which completed Phase 2 trials.

Differentiator

Problem solved

Functional benefit

Brands

  • OLT1177®: Pharmaceutical grade formulation of dapansutrile, a registered trademark of Olatec Therapeutics in the United States and other countries.

Products and services

  • Dapansutrile (OLT1177®) Dapansutrile (lab code: OLT1177®) is Olatec's lead compound — an oral, selective small-molecule NLRP3 inflammasome inhibitor that prevents formation of the NLRP3 inflammasome and inhibits production of pro-inflammatory cytokines IL-1β and IL-18. It is being developed for patients with acute and chronic inflammatory diseases mediated by Interleukin-1, including acute gout flares (PODAGRA trials), heart failure, type 2 diabetes (DAPAN-DIA), Parkinson's disease (DAPA-PD), and advanced melanoma (DREAM trial in combination with pembrolizumab).
  • OLT Analogues Platform Platform of approximately 40-60 structurally related NLRP3 inhibitor compounds (OLT Analogues), representing a new class of pharmaceuticals for treating inflammatory diseases beyond the lead compound dapansutrile. Protected by a global patent portfolio of more than 180 patents and patent applications.
  • OLT1177® Gel (Topical Dapansutrile) Topical gel formulation of dapansutrile (OLT1177®) that has completed Phase 2 clinical trials for treatment of moderate-to-severe osteoarthritis of the knee.

Quantifiable outcome

  • Phase 2a gout trial met primary and secondary endpoints demonstrating clinical benefit, safety, and reduction in systemic inflammation
  • +3 more outcomes

Companies that use Olatec Therapeutics

Customer profile

Segments1 record

Ideal customer profiles3 records

Olatec Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Olatec Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Cambridge University Hospitals NHS Foundation Trust / University of CambridgecoreStrategic or Co-development PartnerThe DAPA-PD Phase 2 clinical trial is being conducted at Cambridge University Hospitals under principal investigator Dr. Caroline Williams-Gray. The trial evaluates dapansutrile safety, tolerability, inflammation biomarkers, and preliminary efficacy over 12 months in early-stage Parkinson's disease patients.
  • Medical University of InnsbruckcoreStrategic or Co-development PartnerCollaboration with Dr. Nadia Stefanova at the Medical University of Innsbruck for preclinical Parkinson's disease studies funded by The Michael J. Fox Foundation, assessing dapansutrile's effects on motor symptoms and neuroinflammation in transgenic mouse models.
  • Duke Cancer InstitutecoreStrategic or Co-development PartnerThe DREAM Trial (Phase 1/2) evaluating dapansutrile in combination with pembrolizumab (Keytruda) in patients with PD-1 refractory advanced melanoma is being led by Principal Investigator April Salama MD at The Duke Cancer Institute.
  • Merck & Co., Inc.coreStrategic or Co-development PartnerMerck supports the DREAM Trial investigating dapansutrile (OLT1177) in combination with pembrolizumab (Keytruda) for PD-1 refractory advanced melanoma. The collaboration addresses inflammatory-driven resistance to anti-PD-1 therapies.
  • University Hospital Basel / University of BaselcoreStrategic or Co-development PartnerDr. Marc Donath, Chief Physician in Endocrinology, Diabetes and Metabolism at University of Basel, serves as Principal Investigator for the DAPAN-DIA Phase 2 trial in type 2 diabetes. Dr. Donath was recently appointed Medical Director of the Diabetes Centre at University Hospital Montreal.
  • National Jewish HealthminorStrategic or Co-development PartnerPartnership with National Jewish Health for the Phase 2 clinical trial of dapansutrile in COVID-19, led by Principal Investigator Dr. Michael Wechsler.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Olatec Therapeutics competitors and assessment

Company assessment

Emerging players

  • AnaptysBio: Clinical-stage immunology biotech developing IL-1 pathway antibodies (e.g., anti-IL-1R). Comparable as an inflammation-focused biotech targeting the same IL-1 axis Olatec's NLRP3 platform modulates.
  • Quench Bio: Emerging biotech focused on NLRP3 inflammasome inhibition for inflammatory diseases. Comparable as an early-stage player targeting the same pathway with selective small-molecule approaches.
  • ChemoCentryx (Amgen): Developed avacopan (Tavneos), an anti-C5aR therapy addressing IL-1-driven inflammation, and was acquired by Amgen in 2022. Comparable as an IL-1 pathway-adjacent biotech commercializing inflammation therapeutics.
  • Kiniksa Pharmaceuticals: Commercial-stage immunology biotech with multiple inflammation assets. Comparable as a clinical-to-commercial-stage company developing therapeutics for IL-1-mediated and other inflammatory diseases.

Direct peers

  • IFM Therapeutics (now Bristol-Myers Squibb): IFM developed small-molecule NLRP3 inhibitors (IFM-2427/NDPK-A) and was acquired by BMS in 2017 for up to $2.3B. It is the most direct competitor in the selective oral NLRP3 space, with deeper resources behind the same target Olatec is pursuing.
  • Inflazome (now Roche): Inflazome developed brain-penetrant NLRP3 inhibitors and was acquired by Roche in 2020 for €380M. It is the closest direct peer in NLRP3 inhibition with a similar small-molecule, orally bioavailable approach across inflammatory diseases.
  • NodThera: Private UK-based biotech developing brain-penetrant NLRP3 inhibitors for inflammatory and neurodegenerative diseases. Directly comparable to Olatec as a clinical-stage, venture-backed NLRP3 platform play.

Broad incumbents

  • Novartis: Acquired IFM Tre's NLRP3 program from BMS in 2019 and is advancing multiple NLRP3 candidates. Comparable as a broad incumbent developing selective NLRP3 inhibitors across inflammatory indications.
  • Bristol-Myers Squibb: Holds the IFM Tre-derived NLRP3 program following its 2017 acquisition of IFM Therapeutics. As a large incumbent with multiple NLRP3 candidates in development, BMS represents a key competitive and potential M&A counterparty.

Regional players

  • Zydus Cadila: Indian pharmaceutical company developing its own NLRP3 inhibitor program. Comparable as a regional player pursuing the same target class, though primarily serving the Indian market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Olatec Therapeutics social profiles

Digital presence

Olatec Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Olatec Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

Olatec Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Olatec Therapeutics funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Olatec Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Olatec Therapeutics

What does Olatec Therapeutics do?

Olatec Therapeutics is a privately held, clinical-stage biopharmaceutical company developing dapansutrile (OLT1177®), an oral selective NLRP3 inflammasome inhibitor that blocks the production of pro-inflammatory cytokines IL-1β and IL-18, for the treatment of acute and chronic inflammatory diseases including gout, heart failure, type 2 diabetes, Parkinson's disease, melanoma, and other IL-1 mediated conditions. The company also maintains a broader platform of approximately 40-60 structurally related OLT Analogues.

Is Olatec Therapeutics a public or private company?

Olatec Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Olatec Therapeutics founded?

Olatec Therapeutics was founded in 2016. It employs 11 to 50 people.

Where is Olatec Therapeutics based?

Olatec Therapeutics is headquartered in New York, United States, in the North America region.

How does Olatec Therapeutics make money?

One revenue line is on record: pharmaceutical Development and Commercialization.

Who are Olatec Therapeutics's main competitors?

Emerging players on record are AnaptysBio, Quench Bio, ChemoCentryx (Amgen) and Kiniksa Pharmaceuticals. Direct peers are IFM Therapeutics (now Bristol-Myers Squibb), Inflazome (now Roche) and NodThera. Broad incumbents are Novartis and Bristol-Myers Squibb. Zydus Cadila is listed as a regional player.

Does Olatec Therapeutics have an API?

No public API is recorded for Olatec Therapeutics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comParkinson's Disease Market: Accelerating Growth and Pipeline Impact by 2034 - DelveInsight | FAScinate Therapeutics, Hoffmann-La Roche, Pharma Two B Ltd., Neuropore Therapies, Olatec Therapeutics, UCBDelveInsight's market research report projects the Parkinson's Disease market will grow from approximately USD 3,539 million in 2025 at a notable CAGR through 2034, driven by rising disease prevalence, improved diagnostics, and new therapeutic approvals. Key clinical developments include Roche advancing prasinezumab to Phase III, AbbVie filing for FDA approval of tavapadon, and the FDA approving Vyalev for advanced Parkinson's, alongside setbacks such as AstraZeneca's Bydureon failing Phase III and UCB discontinuing minzasolmin. The report covers market sizes across the US (~$1,883M in 2023), EU4/UK (~$988M), and Japan, with Germany showing the highest European prevalence.PR NewswireFirst Parkinson's Patients Treated in Landmark Phase 2 Trial of Dapansutrile - Expanding a Leading Oral NLRP3 Inhibitor into Neurological DiseasesOlatec Therapeutics announced that two patients have been enrolled in a Phase 2 trial of dapansutrile for Parkinson's disease at Cambridge University Hospitals, marking its entry into neurological disease trials. The trial evaluates safety, biomarkers, and preliminary efficacy over 12 months, expanding from earlier trials in other inflammatory and chronic diseases.MorningstarFirst Parkinson's Patients Treated in Landmark Phase 2 Trial of Dapansutrile - Expanding a Leading Oral NLRP3 Inhibitor into Neurological DiseasesOlatec Therapeutics announced that two patients have been randomized in the DAPA-PD Phase 2 clinical trial evaluating dapansutrile for Parkinson's disease treatment at Cambridge University Hospitals/University of Cambridge, marking the first 12-month study of an NLRP3 inhibitor in PD. The trial is funded by Cure Parkinson's and Van Andel Institute through the International Linked Clinical Trials program and will assess safety, tolerability, inflammation biomarkers, and preliminary efficacy over 12 months in early-stage PD patients. Dapansutrile, an oral NLRP3 inhibitor, is expanding from ongoing trials in gout, advanced melanoma, and type 2 diabetes into neurological diseases, with preclinical studies showing reduced motor impairment and dopaminergic neurodegeneration.PR NewswireOlatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson's StudiesOlatec Therapeutics presented preclinical data at The Michael J. Fox Foundation's Parkinson's Disease Research Exchange forum showing that dapansutrile, its NLRP3 inhibitor drug candidate, produced disease-modifying effects in two mouse models of Parkinson's disease, including inhibiting neuroinflammation, improving motor deficits, protecting neurons, and normalizing approximately 75% of disease-associated microglial gene signatures. The studies, funded by MJFF and conducted by Dr. Nadia Stefanova at the Medical University of Innsbruck, support the translational rationale for dapansutrile's planned Phase 2 trial expected to begin enrolling soon at the University of Cambridge in patients dosed for 12 months.PR NewswireAndy Cunningham Joins Olatec Therapeutics Board of DirectorsOlatec Therapeutics, Inc. announced that Andy Cunningham has joined its Board of Directors, succeeding Valentín Campos who retired after nine years of service. Cunningham brings four decades of expertise in strategic communication, marketing, and branding, having previously worked with technology leaders including Steve Jobs on launches at Apple, NeXT, and Pixar, as well as companies such as Google, Facebook, and Adobe. The company highlighted her appointment as part of its mission to advance dapansutrile, its lead NLRP3 inhibitor drug candidate, into later-stage clinical development for treating chronic inflammation.Clinical Trials ArenaOlatec initiates dapansutrile Phase II diabetes trialOlatec Therapeutics has initiated a Phase II clinical trial for its NLRP3 inhibitor, dapansutrile, targeting patients with type 2 diabetes and related complications. The DAPAN-DIA Study aims to enroll approximately 300 patients across multiple European centers over a six-month period. The trial is funded by the European Union and the Swiss Government through the INTERCEPT-T2D initiative.Cambridge University HospitalsDrug trial brings hope to Parkinson’s patientsCure Parkinson’s has funded a clinical trial led by the University of Cambridge and Addenbrooke’s Hospital to test the anti-inflammatory drug dapansutrile for treating Parkinson’s disease. The phase trial will involve 36 patients over 12 months to assess the drug's safety, its ability to reduce brain inflammation, and its potential to slow disease progression. Dapansutrile is owned by Olatec Therapeutics Inc, which is developing the compound as an NLRP3 inhibitor.Business Wire BlogOlatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson’s Disease ProgressioThe Michael J. Fox Foundation awarded a grant to Olatec Therapeutics to support preclinical research evaluating dapansutrile in animal models of Parkinson’s disease progression. In collaboration with the Medical University of Innsbruck, Olatec will study the compound's effects on motor symptoms and neuroinflammation in mice. This funding aims to accelerate the development of potential therapeutic interventions for Parkinson's disease.BioSpaceOlatec Therapeutics Awarded a Grant from The Michael J. Fox Foundation in Collaboration With Medical University of Innsbruck to Evaluate Dapansutrile in Animal Models of Parkinson’s Disease ProgressioOlatec Therapeutics has been awarded a grant from The Michael J. Fox Foundation to conduct preclinical research on its lead compound, dapansutrile, in collaboration with the Medical University of Innsbruck. The study aims to evaluate the drug's potential to reduce neuroinflammation and α-synuclein aggregation in animal models of Parkinson’s disease progression. This funding supports Olatec's efforts to advance dapansutrile toward clinical trials for treating this neurodegenerative condition.Business Wire BlogOlatec Therapeutics Announces the Final Closing, Led by Sanders Morris Harris, on Its $40 Million Series A Financing RoundOlatec Therapeutics completed the final closing of its $40 million Series A financing round, led by Sanders Morris Harris. The funds will be used to advance Olatec's lead compound, dapansutrile, into later-stage clinical development for inflammatory diseases. Advection Growth Capital also participated in the investment, and investor Kenneth Wells MD is joining the company's Board of Directors.